CSPG4 and melanoma: An anti-CSPG4 scFv antibody fragment fused with human TRAIL (TNF-related apoptosis-inducing ligand) was designed to deliver pro-apoptotic TRAIL-signalling activity when bound to CSPG4+ melanoma cells, while inhibiting antitumourigenic signalling via CSPG4 downstream signal blocking.